Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK D1225N |
Therapy | Crizotinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK D1225N | lung adenocarcinoma | predicted - sensitive | Crizotinib | Case Reports/Case Series | Actionable | In a clinical case study, Xalkori (crizotinib) treatment resulted in a partial response in a patient with metastatic lung adenocarcinoma harboring ALK D1225N (PMID: 37529699). | 37529699 |
PubMed Id | Reference Title | Details |
---|---|---|
(37529699) | Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors. | Full reference... |